Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A

SSZSE:300357
21.58
CNY
-0.15
(-0.69%)
0.80EPS
24.91P/E
10.64BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.46
0.51
0.6
0.74
0.96
1.22
1.22
1.54
1.71
1.62
1.77
2.03
2.14
Basic EPS, GAAP
0.15
0.19
0.23
0.25
0.36
0.44
0.57
0.53
0.65
0.67
0.59
0.61
0.73
0.82
Free Cash Flow per Basic Share
0.09
0.12
0.16
0.17
0.24
0.28
0.25
0.36
0.46
0.33
0.33
0.28
0.58
- -
Dividend per Share
- -
0.06
0.09
0.11
0.08
0.12
0.14
0.18
0.16
0.2
0.2
0.19
0.22
0.25
Book Value per Share
0.54
0.98
1.11
1.25
1.53
1.85
2.43
2.78
3.32
3.78
4.17
4.5
5
5.6
Tangible Book Value per Share
0.5
0.94
1.06
1.18
1.43
1.62
2.12
2.46
2.98
3.42
3.81
4.15
4.68
5.32
Basic Weighted Avg Shares
467
520
523
523
524
524
524
524
524
524
524
524
524
524
Sales/Revenue/Turnover
194
240
267
312
386
501
639
636
808
896
848
925
1,062
1,119
Operating Margin (%)
42.28
45.02
48.18
48.06
53.7
50.64
49.79
46.32
45.32
46.34
37
35.94
39.01
40.39
Depreciation Expense
4
4
4
6
6
7
10
15
25
26
38
51
56
- -
Net Income, GAAP
71
100
118
129
186
233
298
278
338
349
310
318
381
427
Effective Tax Rate (%)
15.11
16.26
15.01
14.91
15.01
15.06
15.36
16.39
16.97
15.81
14.58
16.63
14.93
14.12
Profit Margin (%)
36.45
41.57
44.11
41.4
48.27
46.51
46.66
43.77
41.85
38.92
36.57
34.34
35.86
38.19
Working Capital
183
431
460
503
614
724
990
1,110
1,234
1,374
1,393
1,469
1,617
1,813
LT Debt
- -
- -
- -
- -
- -
- -
- -
5
2
12
21
8
9
8
Total Equity
252
514
583
656
801
995
1,352
1,528
1,797
2,027
2,304
2,459
2,712
3,016
Return on Invested Capital (%)
31.76
24.41
20.7
20.85
25.09
25.26
24.52
18.54
19.18
17.01
13.29
12.65
14.27
14.89
Return on Capital (%)
32.58
25.05
20.69
20.26
25.11
24.98
25.9
19.87
20.94
18.83
14.78
13.7
15.13
15.63
Return on Common Equity (%)
32.57
26.01
21.49
20.86
25.55
26.3
26.63
20.42
21.18
18.77
14.9
14
15.32
15.83

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
9
9
4
LT Borrowings
- -
- -
- -
LT Finance Leases
10
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
524
524
524
Market Capitalization
13,446
12,210
10,644

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,764
1,807
1,976
Cash, Cash Equivalents & STI
1,325
1,346
1,334
Accounts Receivable, Net
241
224
325
Inventories
54
53
48
Total Current Liabilities
68
198
163
Payables & Accruals
- -
- -
- -
ST Debt
9
9
4
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.88%
12.21%
10.29%
Free Cash Flow
19.11%
18.95%
110.32%
Net Income, GAAP
13.61%
7.17%
19.86%
Sales/Revenue/Turnover
15.39%
11.29%
14.81%
Total Cash Common Dividend
11.57%
5.09%
18.32%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
216
213
301
195
925
2025
228
256
- -
209
1,062
2026
253
261
396
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.14
0.23
0.09
0.61
2025
0.14
0.2
- -
0.07
0.73
2026
0.23
0.18
0.34
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.19
- -
0.19
2025
0.1
- -
- -
- -
0.22
2026
0.1
- -
0.15
- -
- -

Company Description

CEO
Mushuang Hu
Full Time Employees
1,808
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 636, Zhiyuan North Road Huzhou ZH China 313200
IPO Date
Jan 7, 2014
Business
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages primarily in the research, development, manufacture, and sale of bio-pharmaceutical products. Its core offerings include recombinant protein drugs, monoclonal antibodies, small molecule chemical drugs, and innovative biological therapeutics. The company provides products for various therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Wolwo Bio-Pharmaceutical operates its business across China and extends export activities internationally. Founded in 2001, the company is headquartered in Zhejiang, China. In recent years, Zhejiang Wolwo Bio-Pharmaceutical has made strategic advancements including new product launches in innovative biologics and expansions in research collaborations to enhance its pharmaceutical pipeline. The company has also pursued partnerships and alliances aimed at accelerating drug development and market penetration. There have been no recent reports of rebranding or major structural reorganizations, but operational expansions and product diversification have been key focus areas within the last two years. The company operates within the pharmaceutical and biotechnology industry, targeting hospitals, medical institutions, and healthcare providers primarily in the Chinese market, with growing international outreach. Its business segments include biologics manufacturing, chemical drug production, and contract research services. Zhejiang Wolwo Bio-Pharmaceutical maintains subsidiaries focused on specific therapeutic segments to streamline development and commercialization efforts. This comprehensive positioning reflects Zhejiang Wolwo Bio-Pharmaceutical’s ongoing commitment to advancing biopharmaceutical innovation and expanding its product portfolio in both domestic and international markets.